← Back to Clinical Trials
Recruiting NCT06745609

NCT06745609 Prehabilitation Prior to Surgery for Kidney Tumors

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT06745609
Status Recruiting
Phase
Sponsor Herlev and Gentofte Hospital
Condition Renal Cancer
Study Type INTERVENTIONAL
Enrollment 60 participants
Start Date 2025-01-21
Primary Completion 2027-03

Eligibility & Interventions

Sex All sexes
Min Age 65 Years
Max Age N/A
Study Type INTERVENTIONAL
Interventions
Prehabilitation

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.

This trial targets 60 participants in total. It began in 2025-01-21 with a primary completion date of 2027-03.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

The goal of this clinical trial is to examine if one month of general health optimization before surgery for kidney tumors can help participants recover more quickly from surgery. The optimization process is called prehabiliation, and will last one month. It consists of 1. A comprehensive health assessment 2. Assisted smoking cessation 3. A home exercise program. The investigators will compare an intervention group receiving one month of prehabilitation with a control group receiving the standard of care. Some of the main questions the investigators want to answer are * Are participants in the intervention group more satisfied with their quality of recovery after surgery? * Do participants in the intervention group maintain more of their physical abilites compared to the control group?

Eligibility Criteria

Inclusion Criteria: * 65 years or older * cT1 kidney tumor, scheduled for either partial or radical nephrectomy. * Clinical Frailty Scale 3-6 Exclusion Criteria: * It is determined by an attending physician, or at a multi-disciplinary team-conference, that a 2-4 week postponement of surgery will not be beneficial for the participant. * Participant does not understand Danish og English

Contact & Investigator

Central Contact

Marie M Haslund, MD

✉ marie.mykloey.haslund@regionh.dk

📞 004538682699

Frequently Asked Questions

Who can join the NCT06745609 clinical trial?

This trial is open to participants of all sexes, aged 65 Years or older, studying Renal Cancer. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT06745609 currently recruiting?

Yes, NCT06745609 is actively recruiting participants. Contact the research team at marie.mykloey.haslund@regionh.dk for enrollment information.

Where is the NCT06745609 trial being conducted?

This trial is being conducted at Herlev, Denmark.

Who is sponsoring the NCT06745609 clinical trial?

NCT06745609 is sponsored by Herlev and Gentofte Hospital. The trial plans to enroll 60 participants.

Related Trials

Related Intelligence Guides

In-depth guides covering this condition's trials, eligibility, and what to expect.

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology